'Radical rethink needed to tackle hunger, obesity'

Agencies
January 29, 2019

Paris, Jan 29: To defeat the intertwined pandemics of obesity, hunger and climate change, governments must curb the political influence of major corporations, said a major report Monday calling for a 'global treaty' similar to one for tobacco control.

But this will not happen unless ordinary citizens demand a "radical rethink" of the relationship between policymakers and business, nearly four dozen experts from The Lancet Commission on Obesity concluded.

"Powerful opposition from vested interests, lack of political leadership, and insufficient societal demand for change are preventing action," they said in a statement.

Nearly a billion people are hungry and another two billion are eating too much of the wrong foods, causing epidemics of obesity, heart disease and diabetes.

Unhealthy diets account for up to 11 million premature deaths every year, according to the most recent Global Disease Burden report.

"Malnutrition in all its forms -- including undernutrition and obesity -- is by far the biggest cause of ill-health and premature death globally," said Commission co-chair Boyd Swinburn, a professor at the University of Aukland.

"Both undernutrition and obesity are expected to be made significantly worse by climate change."

The way in which food is currently produced, distributed and consumed not only fuels the hunger and obesity pandemics, it also generates 25 to 30 percent of planet-warming greenhouse gas emissions.

Cattle production alone accounts for more than half of those gases, in the form of methane-laden flatulence and CO2 when forests -- especially in Brazil -- are cleared to make room for livestock.

A transport system dominated by cars contributes another 15 to 25 percent of emissions, and supports a sedentary lifestyle.

 "Underpinning all of these are weak political governance, the unchallenging economic pursuit of GPD growth, and the powerful commercial engineering of overconsumption," the report said.

"Undernutrition is declining too slowly to meet global targets, no country has reversed its obesity epidemic, and comprehensive policy responses to the threat of climate change have barely begun."

Despite 30 years of warnings from science about the dire impacts of global warming, CO2 emissions hit record levels in 2017 and again last year.

Because all these problems are interwoven, the answers must be too, the researchers emphasised.

"Joining three pandemics" -- hunger, obesity, climate -- "together as 'The Global Syndemic' allows us to consider common drivers and shared solutions."

Another Lancet Commission report published last week calling for a dramatic shift in global diet to improve health and avoid "catastrophic" damage to the planet.

"Until now, undernutrition and obesity have been seen as polar opposites of either too few or too many calories," said Swinburn.

"In reality, they are both driven by the same unhealthy, inequitable food systems, underpinned by the same political economy."

The report calls for a Framework Convention on Food Systems -- similar to global conventions for tobacco control and climate change -- to restrict the influence of the food industry.

The experts argue that economic incentives must be overhauled.

Some five trillion dollars (4.4 trillion euros) in government subsidies for fossil fuels and large-scale agribusiness should be rechanneled toward "sustainable, healthy and environmentally friendly activities," they said.

To sharply reduce red meat consumption, for example, the report favours high taxes, abolishing subsidies, along with transparent health and environment labelling.

In addition, they favour the creation of a one billion dollar philanthropic fund to support grassroots action.

"Support from civil society is crucial to break the policy deadlock," said co-author William Dietz, a professor at George Washington University.

"As with other social movements -- such as campaigns to introduce sugary drink taxes -- efforts ... are more likely to begin at the community, city or state level."

Nearly all facets of daily life are at play.

"Tackling 'The Global Syndemic' requires an urgent rethink of how we eat, live, consume and move," said Richard Horton, editor-in-chief of The Lancet.

The two Lancet reports are not the only urgent appeal from science in recent months. In October, the UN's Intergovernmental Panel on Climate Change likewise called for an economic and social "paradigm shift" to avoid global chaos.

Health advocates and climate experts hailed The Lancet commission's sweeping call for deep change.

"For too long we have been day-dreaming our way to a diseased future," said Katie Dain, CEO of the Noncommunicable Disease Alliance.

"A food system that secures a better diet for this and the immediate next generations will save millions of lives and, at the same time, help save the planet."

Industry representatives and libertarians slammed the findings as overwrought and an assault on free choice.

"Nanny-state zealots are no longer hiding their intention to use the anti-tobacco blueprint to control other areas of our lives," said Christopher Snowdon, head of lifestyle economics at the London-based Institute of Economic Affairs.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
April 17,2020

Washington DC, Apr 17: In recent research, scientists have linked the emotional, social and psychiatric problems in children and adolescents with higher levels of genetic vulnerability for adult depression. The study implies that the genetics passed from parents may be linked with psychiatric problems in children and adolescents and may also leading to depression in adults.

University of Queensland scientists made the finding while analysing the genetic data of more than 42,000 children and adolescents from seven cohorts across Finland, the Netherlands, Norway, Sweden and the UK.

Professor Christel Middeldorp said that researchers have also found a link with a higher genetic vulnerability for insomnia, neuroticism and body mass index.

"By contrast, study participants with higher genetic scores for educational attainment and emotional well-being were found to have reduced childhood problems," Professor Middeldorp said.

"We calculated a person's level of genetic vulnerability by adding up the number of risk genes they had for a specific disorder or trait and then made adjustments based on the level of importance of each gene We found the relationship was mostly similar across ages," Middeldorp added.

The results indicate there are shared genetic factors that affect a range of psychiatric and related traits across a person's lifespan.

Middeldorp said that around 50 per cent of children and adolescents with psychiatric problems, such as attention deficit hyperactivity disorder (ADHD), continue to experience mental disorders as adults, and are at risk of disengaging with their school community among other social and emotional problems.

"Our findings are important as they suggest this continuity between childhood and adult traits is partly explained by genetic risk," the Professor said.

"Individuals at risk of being affected should be the focus of attention and targeted treatment," Middeldorp continued.

"Although the genetic vulnerability is not accurate enough at this stage to make individual predictions about how a person's symptoms will develop over time, it may become so in the future, in combination with other risk factors. And, this may support precision medicine by providing targeted treatments to children at the highest risk of persistent emotional and social problems," Middeldorp added.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
July 2,2020

The American pharmaceutical giant Pfizer Inc. and the European biotechnology company BioNTech SE have conducted an experimental trial of a COVID-19 vaccine candidate and found it to be safe, well-tolerated, and capable of generating antibodies in the patients.

The study, which is yet to be peer-reviewed, describes the preliminary clinical data for the candidate vaccine -- nucleoside-modified messenger RNA (modRNA), BNT162b1.

It said the amount of antibodies produced in participants after they received two shots of the vaccine candidate was greater than that reported in patients receiving convalescent plasma from recovered COVID-19 patients.

"I was glad to see Pfizer put up their phase 1 trial data today. Virus neutralizing antibody titers achieved after two doses are greater than convalescent antibody titers," tweeted Peter Hotez, a vaccine scientist from Baylor College of Medicine in the US, who was unrelated to the study.

Researchers, including those from New York University in the US, who were involved in the study, said the candidate vaccine enables human cells to produce an optimised version of the receptor binding domain (RBD) antigen -- a part of the spike (S) protein of SARS-CoV-2 which it uses to gain entry into human cells.

"Robust immunogenicity was observed after vaccination with BNT162b1," the scientists noted in the study.

They said the program is evaluating at least four experimental vaccines, each of which represents a unique combination of mRNA format and target component of the novel coronavirus, SARS-CoV-2.

Based on the study's findings, they said BNT162b1 could be administered in a quantity that was well tolerated, potentially generating a dose dependent production of immune system molecules in the patients.

The research noted that patients treated with the vaccine candidate produced nearly 1.8 to 2.8 fold greater levels of RBD-binding antibodies that could neutralise SARS-CoV-2.

"We are encouraged by the clinical data of BNT162b1, one of four mRNA constructs we are evaluating clinically, and for which we have positive, preliminary, topline findings," said Kathrin U. Jansen, study co-author and Senior Vice President and Head of Vaccine Research & Development, Pfizer.

"We look forward to publishing our clinical data in a peer-reviewed journal as quickly as possible," Jansen said.

According to Ugur Sahin, CEO and Co-founder of BioNTech, and another co-author of the study, the preliminary data are encouraging as they provide an initial signal that BNT162b1 is able to produce neutralising antibody responses in humans.

He said the immune response observed in the patients treated with the experimental vaccine are at, or above, the levels observed from convalescent sera, adding that it does so at "relatively low dose levels."

"We look forward to providing further data updates on BNT162b1," Sahin said.

According to a statement from Pfizer, the initial part of the study included 45 healthy adults 18 to 55 years of age.

It said the priliminary data for BNT162b1 was evaluated in 24 subjects who received two injections of 10 microgrammes ( g) and 30 g -- 12 subjects who received a single injection of 100 g, and 9 subjects who received two doses of a dummy vaccine.

The study noted that participants received two doses, 21 days apart, of placebo, 10 g or 30 g of BNT162b1, or received a single dose of 100 g of the vaccine candidate.

According to the scientists, the highest neutralising concentrations of antibodies were observed seven days after the second dose of 10 g, or 30 g on day 28 after vaccination.

They said the neutralising concentrations were 1.8- and 2.8-times that observed in a panel of 38 blood samples from people who had contracted the virus.

In all 24 subjects who received two vaccinations at 10 g and 30 g dose levels, elevation of RBD-binding antibody concentrations was observed after the second injection, the study noted.

It said these concentrations are 8- and 46.3-times the concentration seen in a panel of 38 blood samples from those infected with the novel coronavirus.

At the 10 g or 30 g dose levels, the scientists said adverse reactions, including low grade fever, were more common after the second dose than the first dose.

According to Pfizer, local reactions and systemic events after injection with 10 g and 30 g of BNT162b1 were "dose-dependent, generally mild to moderate, and transient."

It said the most commonly reported local reaction was injection site pain, which was mild to moderate, except in one of 12 subjects who received a 100 g dose, which was severe.

The study noted that there was no serious adverse events reported by the patients.

Citing the limitations of the research, the scientists said the immunity generated in the participants in the form of the T cells and B cells of their immune system, and the level of immunity needed to protect one from COVID-19 are unknown.

With these preliminary data, along with additional data being generated, Pfizer noted in the statement that the two companies will determine a dose level, and select among multiple vaccine candidates to seek to progress to a large, global safety and efficacy trial, which may involve up to 30,000 healthy participants if regulatory approval to proceed is received.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
February 4,2020

Despite tremendous advances in treatment of congenital heart disease (CHD), a new global study shows that the chances for a child to survive a CHD diagnosis is significantly less in low-income countries.

The research revealed that nearly 12 million people are currently living with CHD globally, 18.7 per cent more than in 1990.

The findings, published in The Lancet, is drawn from the first comprehensive study of congenital heart disease across 195 countries, prepared using data from the Global Burden of Diseases, Injuries and Risk Factors Study 2017 (GBD).

"Previous congenital heart estimates came from few data sources, were geographically narrow and did not evaluate CHD throughout the life course," said the study authors from Children's National Hospital in the US.

This is the first time the GBD study data was used along with all available data sources and previous publications - making it the most comprehensive study on the congenital heart disease burden to date.

The study found a 34.5 per cent decline in deaths from congenital disease between 1990 to 2017. Nearly 70 per cent of deaths caused by CHD in 2017 (180,624) were in infants less than one year old.

Most CHD deaths occurred in countries within the low and low-middle socio-demographic index (SDI) quintiles.

Mortality rates get lower as a country's Socio-demographic Index (SDI) rises, the study said.

According to the researchers, birth prevalence of CHD was not related to a country's socio-demographic status, but overall prevalence was much lower in the poorest countries of the world.

This is because children in these countries do not have access to life saving surgical services, they added.

"In high income countries like the United States, we diagnose some heart conditions prenatally during the 20-week ultrasound," said Gerard Martin from Children's National Hospital who contributed to the study.

"For children born in middle- and low-income countries, these data draw stark attention to what we as cardiologists already knew from our own work in these countries -- the lack of diagnostic and treatment tools leads to lower survival rates for children born with CHD," said researcher Craig Sable.

"The UN has prioritised reduction of premature deaths from heart disease, but to meet the target of 'ending preventable deaths of newborns and children under 5 years of age,' health policy makers will need to develop specific accountability measures that address barriers and improve access to care and treatment," the authors wrote.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.